Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics
Open Access
- 29 April 2015
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 4 (5) , 858-873
Abstract
Atopic dermatitis (AD) is the most common inflammatory skin disease. Recent research findings have provided an insight into the complex pathogenic mechanisms involved in this disease. Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are still lacking. Biomarkers of lesional, nonlesional skin, and blood have been developed for baseline as well as after treatment with broad and specific treatments (i.e., cyclosporine A and dupilumab). These biomarkers will help with the development of novel targeted therapeutics and assessment of disease reversal, with the promise of a more personalized treatment approach. Since AD involves more than one subtype (i.e., intrinsic/extrinsic, pediatric/adult, etc.), these molecular fingerprints needs to be validated in all subpopulations with AD.Keywords
Funding Information
- British Association of Dermatologists (Geoffrey Dowling Fellowship)
This publication has 99 references indexed in Scilit:
- One Remarkable Molecule: FilaggrinJournal of Investigative Dermatology, 2012
- Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic responseJournal of Allergy and Clinical Immunology, 2011
- Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalitiesJournal of Allergy and Clinical Immunology, 2011
- Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's HealthJournal of Investigative Dermatology, 2011
- Abnormal skin barrier in the etiopathogenesis of atopic dermatitisCurrent Opinion in Allergy and Clinical Immunology, 2009
- IL-22–producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cellsJournal of Allergy and Clinical Immunology, 2009
- Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathwaysBritish Journal of Dermatology, 2008
- “Outside-to-Inside” (and Now Back to “Outside”) Pathogenic Mechanisms in Atopic DermatitisJournal of Investigative Dermatology, 2008
- Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptidesJournal of Experimental Medicine, 2006
- Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitisNature Genetics, 2006